(3aR,5R,6aR)-2-Morpholinoethyl 5-amino-3a-(3-(trifluoromethyl)-5,6,7,8-tetrahydro-1,6-naphthyridine-6-carbonyl)hexahydrocyclopenta[c]pyrrole-2(1H)-carboxylate | 1537881-55-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: (3aR,5R,6aR)-2-Morpholinoethyl 5-amino-3a-(3-(trifluoromethyl)-5,6,7,8-tetrahydro-1,6-naphthyridine-6-carbonyl)hexahydrocyclopenta[c]pyrrole-2(1H)-carboxylate
• 英文别名: 2-morpholin-4-ylethyl (3aR,5R,6aR)-5-amino-3a-[3-(trifluoromethyl)-7,8-dihydro-5H-1,6-naphthyridine-6-carbonyl]-1,3,4,5,6,6a-hexahydrocyclopenta[c]pyrrole-2-carboxylate
• CAS: 1537881-55-2
• 化学式: C₂₄H₃₂F₃N₅O₄
• 分子量: 511.544
• InChiKey: TYPWMCPPXPWXDJ-YYDVJCTNSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  36
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  101
• 氢给体数：
  1
• 氢受体数：
  10

反应信息

• 作为反应物：
  描述：

  3-甲氧基-四氢-2H-吡喃-4-酮 、 (3aR,5R,6aR)-2-Morpholinoethyl 5-amino-3a-(3-(trifluoromethyl)-5,6,7,8-tetrahydro-1,6-naphthyridine-6-carbonyl)hexahydrocyclopenta[c]pyrrole-2(1H)-carboxylate 在 三乙酰氧基硼氢化钠 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 生成 (3aR,5R,6aR)-2-morpholinoethyl 5-((3-methoxytetrahydro-2H-pyran-4-yl)amino)-3a-(3-(trifluoromethyl)-5,6,7,8-tetrahydro-1,6-naphthyridine-6-carbonyl)hexa-hydrocyclopenta[c]pyrrole-2(1H)-carboxylate
  参考文献：
  名称：

  Discovery and SAR of 5-aminooctahydrocyclopentapyrrole-3a-carboxamides as potent CCR2 antagonists

  摘要：

  SAR study of 5-aminooctahydrocyclopentapyrrole-3a-carboxamide scaffold led to identification of several CCR2 antagonists with potent activity in both binding and functional assays. Their cardiovascular safety and pharmacokinetic properties were also evaluated. (C) 2014 Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmcl.2013.05.024
• 作为产物：
  描述：

  (3aR,5R,6aR)-methyl 2-benzyl-5-(tert-butoxycarbonylamino)octahydrocyclopenta[c]pyrrole-3a-carboxylate 在 4-二甲氨基吡啶 、 氢气 、 palladium(II) hydroxide 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 、 三氟乙酸 、 potassium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 20.0 ℃ 、172.37 kPa 条件下， 生成 (3aR,5R,6aR)-2-Morpholinoethyl 5-amino-3a-(3-(trifluoromethyl)-5,6,7,8-tetrahydro-1,6-naphthyridine-6-carbonyl)hexahydrocyclopenta[c]pyrrole-2(1H)-carboxylate
  参考文献：
  名称：

  Discovery and SAR of 5-aminooctahydrocyclopentapyrrole-3a-carboxamides as potent CCR2 antagonists

  摘要：

  SAR study of 5-aminooctahydrocyclopentapyrrole-3a-carboxamide scaffold led to identification of several CCR2 antagonists with potent activity in both binding and functional assays. Their cardiovascular safety and pharmacokinetic properties were also evaluated. (C) 2014 Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmcl.2013.05.024

文献信息

• [EN] OCTAHYDRO-CYCLOPENTAPYRROLYL ANTAGONISTS OF CCR2<br/>[FR] ANTAGONISTES OCTAHYDRO-CYCLOPENTAPYRROLYL ANTI-CCR2
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2014014901A1

  公开（公告）日：2014-01-23

  The present invention comprises compounds of Formula (I). Formula (I) wherein: R1, R2, R3, R4, R5, Z1 and Z2 are as defined in the specification. The invention also comprises a method of preventing, treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is type II diabetes, obesity and asthma. The invention also comprises a method of inhibiting CCR2 activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula (I).

  本发明包括式(I)的化合物。其中：R1、R2、R3、R4、R5、Z1和Z2如规范中所定义。该发明还包括一种预防、治疗或改善综合症、疾病或疾病的方法，其中所述综合症、疾病或疾病是II型糖尿病、肥胖和哮喘。该发明还包括通过给哺乳动物施用至少一种式(I)化合物的治疗有效量来抑制CCR2活性的方法。
• OCTAHYDRO-CYCLOPENTAPYRROLYL ANTAGONISTS OF CCR2
  申请人：Janssen Pharmaceutica NV

  公开号：US20140024646A1

  公开（公告）日：2014-01-23

  The present invention comprises compounds of Formula (I). wherein: R 1 , R 2 , R 3 , R 4 , R 5 , Z 1 and Z 2 are as defined in the specification. The invention also comprises a method of preventing, treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is type II diabetes, obesity and asthma. The invention also comprises a method of inhibiting CCR2 activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula (I).

  本发明涉及公式（I）的化合物，其中：R1、R2、R3、R4、R5、Z1和Z2如规范中所定义。本发明还涉及一种预防、治疗或改善综合症、失调或疾病的方法，其中所述综合症、失调或疾病是II型糖尿病、肥胖症和哮喘。本发明还涉及一种通过给哺乳动物注射公式（I）至少一种化合物的治疗有效剂量来抑制CCR2活性的方法。
• US9024017B2
  申请人：——

  公开号：US9024017B2

  公开（公告）日：2015-05-05